Perlmutter Cancer Center

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Stage Iv Nsclc
• Age: Between 18 Year(s) - 100 Year(s)
• Gender: Male or Female

• Other Inclusion Criteria:
  

  1. Be willing and able to provide written informed consent/assent for the trial.
  2. Histologically documented, metastatic NSCLC with no previous systemic therapy.
  3. At least 2 distinct measurable metastatic sites, which are 1 cm or larger; patients can have radiation to multiple measurable disease sites as clinically indicated, however, there must be at least 1 measurable non-radiated target lesion for response assessment.
  4. Agreeable to provide archival tissue for correlative studies; if no archival tissue available may obtain a exemption by the study team.

  
  

You may not be eligible for this study if the following are true:

• 1. Participant is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
  2. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
  3. Has a known history of active TB (Bacillus Tuberculosis).

  4. Hypersensitivity to pembrolizumab or any of its excipients.